<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02776878</url>
  </required_header>
  <id_info>
    <org_study_id>DRAMA GIST</org_study_id>
    <nct_id>NCT02776878</nct_id>
  </id_info>
  <brief_title>A Clinical Trial Evaluating the Efficacy and Safety of Dasatinib in Refractory Metastatic GIST</brief_title>
  <official_title>A Prospective, Single-arm, Multi-center Clinical Trial Evaluating the Efficacy and Safety of Dasatinib in RefrActory MetAstatic Gastrointestinal Stromal Tumor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Cancer Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether dasatinib is effective and safe in the
      treatment of refractory metastatic gastrointestinal stromal tumor
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survive, calculated from registration until progression or death</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival, overall survival will be calculated from registration until death</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse drug reactions according to NCI CTCAE v4.0</measure>
    <time_frame>2 years, Tolerability will be assessed based on the frequency and severity of Adverse Drug Reactions (ADR) coded according to NCI CTCAE v4.0.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response, according to Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 criteria</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor control probability, defined as CR＋PR＋SD, determined according to RECIST 1.1 criteria</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">57</enrollment>
  <condition>Gastrointestinal Stromal Tumor</condition>
  <arm_group>
    <arm_group_label>Dasatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dasatinib is given orally 50 mg 2 times a day for the first week, if subject is tolerate, then increased to 70 mg 2 times a day. Dasatinib will be continued until unacceptable toxicity and progression.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dasatinib</intervention_name>
    <arm_group_label>Dasatinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed recurrent/metastatic gastrointestinal stromal tumor (GIST).
             Immunohistochemically, the detection KIT and/or DOG-1 are/is positive

          -  Patients must have measurable disease meeting the requirement of RECIST 1.1

          -  Received the gene mutation detection of c - kit/PDGFRA

          -  Subjects with mutation in exon 11, in exon 9 and wild type c-kit/PDGFRA have failed to
             imatinib and sunitinib

          -  Subjects with primary mutation in exon 17 or 18 have failed to imatinib

          -  Subjects with primary mutation in exon 11 and secondary mutation in exon 17 or 18 have
             failed to imatinib

          -  Subjects with mutation in exon 18 of PDGFRA,have received TKI or not

          -  Eastern Cooperative Oncology Group (ECOG) performance status = 0-2

          -  Expected OS ≥3 months

          -  Ability to understand and the willingness to sign a written informed consent document

          -  Subject will comply with the study procedures and therapy

        Exclusion Criteria:

          -  Local or metastatic GIST is resectable

          -  Unable to receive the gene mutation detection of c-kit
             (c-kitproto-oncogeneprotein)/PDGFRA

          -  AST and/or ALT &gt; 2.5 times ULN, or Bilirubin &gt;1.5 times upper limit of normal (ULN)

          -  Neutrophil count &lt; 1.5 x 10^9/L, or Platelet count &lt;75 x 10^9/L, or Hemoglobin&lt;90g/L

          -  Cr &gt;1.5×ULN

          -  Other malignancy within the past 5 years except for adequately treated carcinoma in
             situ of the cervix or cutaneous basal cell carcinoma

          -  Known brain metastasis, spinal cord compression, carcinomatous meningitis, or cerebral
             or soft meningeal disease through CT or MRI during screening stage

          -  Within the past 5 years, subjects have one of the following disease: myocardial
             infarction, serious/instable angina pectoris, symptomatic congestive heart failure or
             cerebrovascular accident from coronary/peripheral artery bypass grafting

          -  Known human immunodeficiency virus positivity

          -  Joining in other trail

          -  Women who are pregnant or lactating; No contraception for subject during childbearing
             period

          -  Subject with other serious acute and chronic physical or mental problems, or
             laboratory abnormality, will increase the risks associated with trail or drug. It will
             also interference the judgment of the results. In the judgment of the investigator,
             subject is inadequate to participant the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shen Lin</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Li Jian</last_name>
    <phone>008613601310849</phone>
    <email>oncogene@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li Jian</last_name>
      <phone>008613601310849</phone>
      <email>oncogene@163.com</email>
    </contact>
    <investigator>
      <last_name>Shen Lin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wu Xin</last_name>
      <phone>008613683285233</phone>
    </contact>
    <investigator>
      <last_name>Wu Xin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital,Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zhang Xinhua</last_name>
      <phone>008613828463644</phone>
    </contact>
    <investigator>
      <last_name>Zhang Xinhua</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>No.81 Hospital of Chinese People's Liberation Army</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Liu Xiufeng</last_name>
      <phone>008613357837170</phone>
    </contact>
    <investigator>
      <last_name>Liu Xiufeng</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zhou Ye</last_name>
      <phone>008613661736873</phone>
    </contact>
    <investigator>
      <last_name>Zhou Ye</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shanxi Cancer Hospital</name>
      <address>
        <city>Taiyuan</city>
        <state>Shanxi</state>
        <zip>030013</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Liang Xiaobo</last_name>
    </contact>
    <investigator>
      <last_name>Liang Xiaobo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West China Hospital , Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zhang Bo</last_name>
      <phone>008613881952600</phone>
    </contact>
    <investigator>
      <last_name>Zhang Bo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 17, 2016</study_first_submitted>
  <study_first_submitted_qc>May 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 18, 2016</study_first_posted>
  <last_update_submitted>May 17, 2016</last_update_submitted>
  <last_update_submitted_qc>May 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Cancer Hospital</investigator_affiliation>
    <investigator_full_name>Shen Lin</investigator_full_name>
    <investigator_title>MD，PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dasatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

